M Mason

University College London, London, ENG, United Kingdom

Are you M Mason?

Claim your profile

Publications (1)5.08 Total impact

  • Source
    H Payne, M Mason
    [Show abstract] [Hide abstract]
    ABSTRACT: Androgen deprivation therapy (ADT) has traditionally formed the mainstay of treatment for advanced/metastatic prostate cancer (PCa); however, it is now also having an increasingly important role in earlier stages of disease. Indeed, in patients with locally advanced or high-risk localised disease, the addition of neoadjuvant and adjuvant hormone therapy is now considered the standard of care for those men treated with radical radiotherapy. Although luteinising hormone-releasing hormone (LHRH) agonists have been used for many years as ADT, they may be associated with clinical flare and testosterone breakthrough. Newer hormonal agents continue to be developed, such as gonadotropin-releasing hormone antagonists, which reduce testosterone and prostate-specific antigen levels more rapidly than LHRH agonists, without testosterone flare. This review examines ADT use in combination with radiotherapy to improve outcomes in localised or locally advanced disease, and examines some of the latest developments in hormonal therapy for PCa.
    British Journal of Cancer 11/2011; 105(11):1628-34. · 5.08 Impact Factor

Publication Stats

6 Citations
5.08 Total Impact Points

Top co-authors

Top Journals

Institutions

  • 2011
    • University College London
      • Department of Clinical Physiology
      London, ENG, United Kingdom